Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Developing a survivin vaccine for glioblastoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.18
Views: 850

Dr Michael Ciesielski - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Dr Ciesielski speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago about SurVaxM, an investigational vaccine against glioblastoma.

He outlines results from 63 patients treated with standard therapy — surgery followed by chemoradiation and then adjuvant chemotherapy, then the vaccine, in which 91% of patients receiving SurVaxM were still living 12 months after initiating treatment, compared to 61% in a historical analysis of patients treated with standard therapy alone.

Dr Ciesielski also highlights that 96% achieved six-month progression-free survival, compared to 54% among the historical comparison group, and looks forward to further trial expansion.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos


no rating
Cancer care in Latin America

follow us

Core Surgical Training

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation